CV301 consists of a poxvirus-based immunotherapy encoding transgenes for B7.1, intercellular adhesion molecule-1, leukocyte function-associated antigen-3, Carcinoembryonic Antigen and Mucin-1 based on a non-replicating Modified Vaccinia Ankara (MVA) vector. Five subjects with recurrent NSCLC following platinum-based chemotherapy have been treated with CV301 in combination with Nivolumab (four subjects) or pembrolizumab (one subject). Four patients are evaluable for response. One (25%) complete radiological response and three (75%) cases of disease stabilization have been observed. Treatment is well tolerated and the adverse event profile is similar to immune checkpoint inhibitor monotherapy. Overall, 12 patients have been enrolled in this multicenter study. The study has completed accrual and data are being prepared for publication. A poster based on this study was presented at the Annual Meeting of the European Society of Medical Oncology (ESMO) in November 2019. A manuscript related to the trial has been accepted for publication in the International Journal of Cancer.